Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

26.09
+0.04000.15%
Post-market: 26.090.00000.00%16:10 EDT
Volume:320.07K
Turnover:8.34M
Market Cap:1.55B
PE:-10.86
High:26.42
Open:25.99
Low:25.18
Close:26.05
52wk High:40.65
52wk Low:11.70
Shares:59.49M
Float Shares:35.21M
Volume Ratio:0.78
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4031
EPS(LYR):-2.0125
ROE:-45.31%
ROA:-28.46%
PB:4.39
PE(LYR):-12.96

Loading ...

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and Tyra Bioscience (TYRA)

TIPRANKS
·
Jun 16

Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says

MT Newswires Live
·
Jun 10

Tyra Biosciences Is Maintained at Buy by B of A Securities

Dow Jones
·
Jun 10

Tyra Biosciences price target raised to $42 from $37 at BofA

TIPRANKS
·
Jun 10

Jazz Pharmaceuticals : Bofa Global Research Raises Price Objective to $307.00 From $281.00

THOMSON REUTERS
·
Jun 10

Tyra Biosciences : Bofa Global Research Raises Price Objective to $42.00 From $37.00

THOMSON REUTERS
·
Jun 10

Analyst Initiates Buy on Tyra Biosciences, Citing De-Risked Dabogratinib Program and Attractive Entry Ahead of Key Bladder Cancer Data

TIPRANKS
·
Jun 10

Barclays Keeps Their Buy Rating on Tyra Bioscience (TYRA)

TIPRANKS
·
Jun 03

Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor

TIPRANKS
·
Jun 03

Tyra Biosciences stockholders elect three Class II directors at annual meeting

Reuters
·
Jun 03

Tyra Biosciences Rated Buy on Anticipation of Interim SURF302 Dabogratinib Data in FGFR3‑Driven NMIBC

TIPRANKS
·
May 26

Assessing Tyra Biosciences (TYRA) Valuation After Wider Losses And Progress In Dabogratinib Trials

Simply Wall St.
·
May 21

Stock Track | Tyra Biosciences Plummets 5.08% Intraday After Wolfe Research Initiates Coverage with Peer Perform Rating

Stock Track
·
May 20

Tyra Biosciences Initiated at Peer Perform by Wolfe Research

Dow Jones
·
May 19

Tyra Biosciences initiated with a Peer Perform at Wolfe Research

TIPRANKS
·
May 19

Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile?

Simply Wall St.
·
May 16

Jefferies Reaffirms Their Buy Rating on Tyra Bioscience (TYRA)

TIPRANKS
·
May 14

Bank of America Securities Keeps Their Buy Rating on Tyra Bioscience (TYRA)

TIPRANKS
·
May 14

Tyra Biosciences Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
May 14

Tyra Bioscience (TYRA) Gets a Buy from Barclays

TIPRANKS
·
May 14